Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors (Q33359976)

26 July 2017

1 reference

title

Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors (English)

1 reference

26 July 2017

main subject

venous thromboembolism

1 reference

Bengt I Eriksson

1

1 reference

26 July 2017

Ola E Dahl

series ordinal

2

1 reference

26 July 2017

publication date

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

64

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

577-595

1 reference

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

26 July 2017

cites work

1 reference

12 December 2020

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

1 reference

12 December 2020

Managing oral anticoagulant therapy

1 reference

12 December 2020

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

12 December 2020

Direct thrombin inhibitors

1 reference

12 December 2020

Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia

1 reference

12 December 2020

Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance

1 reference

12 December 2020

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

12 December 2020

Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review

1 reference

12 December 2020

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

1 reference

12 December 2020

Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

1 reference

12 December 2020

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

1 reference

12 December 2020

Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.

1 reference

12 December 2020

Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin

1 reference

12 December 2020

The epidemiology of total hip replacement in The Netherlands and Sweden: present status and future needs.

1 reference

12 December 2020

Direct thrombin inhibitors in cardiovascular medicine

1 reference

12 December 2020

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

12 December 2020

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

1 reference

12 December 2020

Catabolism of hirudin and thrombin-hirudin complexes in the rat.

1 reference

12 December 2020

The role of low molecular weight heparin in total knee arthroplasty.

1 reference

12 December 2020

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

12 December 2020

Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery

1 reference

12 December 2020

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

12 December 2020

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

1 reference

12 December 2020

Recombinant hirudin in clinical practice: focus on lepirudin.

1 reference

12 December 2020

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

12 December 2020

Total hip replacement, lower limb blood flow and venous thrombogenesis

1 reference

12 December 2020

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

1 reference

12 December 2020

Assessing the preventability of emergency hospital admissions. A method for evaluating the quality of medical care in a primary care facility

1 reference

12 December 2020

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

12 December 2020

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

12 December 2020

The use of bivalirudin in patients with renal impairment.

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

The Danish Hip Arthroplasty Register.

1 reference

12 December 2020

Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review

1 reference

12 December 2020

Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons

1 reference

12 December 2020

Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

1 reference

12 December 2020

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

12 December 2020

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

12 December 2020

Coagulation changes in elective surgery and trauma

1 reference

12 December 2020

Bivalirudin: a direct thrombin inhibitor

1 reference

12 December 2020

Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

1 reference

12 December 2020

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

1 reference

12 December 2020

1 reference

12 December 2020

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

12 December 2020

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

1 reference

12 December 2020

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

12 December 2020

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

12 December 2020

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

1 reference

12 December 2020

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

12 December 2020

Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations

1 reference

12 December 2020

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

12 December 2020

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

12 December 2020

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

12 December 2020

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender

1 reference

12 December 2020

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

12 December 2020

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

1 reference

12 December 2020

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Clinical pharmacology of bivalirudin

1 reference

12 December 2020

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

12 December 2020

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity

1 reference

12 December 2020

The Finnish Arthroplasty Register: report of the hip register.

1 reference

12 December 2020

Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis.

1 reference

12 December 2020

Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement

1 reference

12 December 2020

Cardiorespiratory and vascular dysfunction related to major reconstructive orthopedic surgery

1 reference

12 December 2020

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

12 December 2020

Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia.

1 reference

12 December 2020

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

1 reference

12 December 2020

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

12 December 2020

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

12 December 2020

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

12 December 2020

Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

12 December 2020

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

12 December 2020

Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

1 reference

12 December 2020

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation

1 reference

12 December 2020

Thrombin and antithrombotics

1 reference

12 December 2020

Treatment of heparin-induced thrombocytopenia

1 reference

12 December 2020

Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery

1 reference

12 December 2020

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

12 December 2020

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

1 reference

12 December 2020

The coagulation cascade: initiation, maintenance, and regulation

1 reference

12 December 2020

Rates and outcomes of primary and revision total hip replacement in the United States medicare population

1 reference

12 December 2020

Pharmacology of r-hirudin in renal impairment

1 reference

12 December 2020

Past incidence and future demand for knee arthroplasty in Sweden: a report from the Swedish Knee Arthroplasty Register regarding the effect of past and future population changes on the number of arthroplasties performed

1 reference

12 December 2020

The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis

1 reference

12 December 2020

Course, management and outcome of oral-anticoagulant-related intracranial haemorrhages

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials

1 reference

12 December 2020

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

12 December 2020

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery

1 reference

12 December 2020

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats

1 reference

12 December 2020

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study

1 reference

12 December 2020

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

1 reference

12 December 2020

10.2165/00003495-200464060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1026799009

0 references

1 reference